A groundbreaking study is testing new ways to bring HIV prevention and PrEP to men whose work keeps them constantly on the road.

It's a balmy afternoon in Mtubatuba, in northern KwaZulu-Natal (KZN), and the local taxi rank is abuzz with activity. Drivers are calling out their routes while others rev their engines, getting ready ...

UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

“This strategy of [switching to bictegravir/emtricitabine/tenofovir alafenamide] is an appealing one for reducing severe interactions, toxicity and pill burden in ...

Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

People in Liverpool are being offered easier access to a pioneering pill which can reduce the risk of contracting HIV by 99%. The city's axess sexual health service is piloting a new online platform ...